Drugs / IRL757
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06699628 | Sep → Nov 2024 | — | Integrative Research Laboratories AB | Completed | No outcome recorded |
| Phase 1 | NCT06493045 | May 2024 → Feb 2025 | — | Integrative Research Laboratories AB | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07461220 | Feb 2026 → May 2027 expected | Parkinson disease | Integrative Research Laboratories AB | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-23 | Integrative Research Laboratories AB | Regulatory IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease irlab.se ↗
IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, has received regulatory and ethical approvals for a Phase Ib study of IRL757 to assess safety, tolerability, and signal finding in patients with Parkinson’s disease who experience apathy. |
| 2025-05-28 | Integrative Research Laboratories AB | Results IRLAB reports positive results from the second part of a Phase I study with IRL757 irlab.se ↗
The results show that IRL757 is well absorbed and provides good exposure in the body following ten days of dosing. |
| 2025-01-31 | Integrative Research Laboratories AB | Results IRLAB reports positive topline results from Phase I study with IRL757 in healthy older adults irlab.se ↗ |
| 2024-10-03 | Integrative Research Laboratories AB | Results Positive data from the first part of IRLAB’s Phase I study with the drug candidate IRL757 irlab.se ↗
The results show that IRL757 is well absorbed, provides good exposure in the body and has a good tolerability and safety profile. |
| 2024-05-06 | Integrative Research Laboratories AB | Regulatory IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757 irlab.se ↗
IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the Swedish Medical Products Agency has approved the initiation of a Phase I clinical study of the drug candidate IRL757. |
All press releases naming this drug 16 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRL757 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06493045 ↗ |
| Route | Oral | “single and multiple ascending oral doses of IRL757” NCT06493045 ↗ |